Periodic Reporting for period 2 - ABwipe (COVID-19 pandemic: An innovative, safe and effective bio-decontamination technology for non-toxic removal of biological agents, including coronavirus)
Okres sprawozdawczy: 2021-08-01 do 2023-01-31
ABL has developed a unique pilot product, the ABD Device, a cellulose based decontamination wipe that incorporates natural binders that can capture and remove all pathogens including viruses, bacteria, fungi and their mutants in a safe and effective manner. The technology consists of non-toxic chemicals that can be safely used on sensitive skin surfaces such as face, around the eyes, nose and mouth and mucosal surfaces to disinfect these ports of entry from pathogens.
Work Objectives:
• To develop the ABwipe, now referred to as the ABD Device, from a laboratory prototype to a commercial large-scale manufacturing environment.
• To obtain external verification of the efficacy of the technology from independent laboratories.
• To gain potential customer insights through pilot studies.
Pilot studies have been carried out with potential customers and the ABD Device has been well received during these review and feedback sessions.
An external laboratory, NeoVirTech, demonstrated the ability of the device to effectively capture and remove between 99.9-99.99% of SARS-CoV-2 from human skin explants.
The product has been developed to be eco-friendly as it is largely made up of biodegradeable material and environmentally safe formulation ingredients.
Despite the travel restrictions of the Covid-19 pandemic, ABL and the ABD Device have been represented at a number of national and international conferences and media articles.